SkyePharma PLC: Flutiform NDA Accepted for Review

Fri. May 22, 2009; Posted: 02:11 AM

LONDON, May 22, 2009 (MARKETWIRE via COMTEX) -- SKYPY | Quote | Chart | News | PowerRating -- e> SKYEPHARMA PLC - Flutiform(TM) NDA Accepted for Review LONDON, UK, 22 May 2009 - SkyePharma PLC (LSE: SKP) today announces that the New Drug Application (NDA) for its lead development product, Flutiform(TM) (fluticasone propionate/formoterol fumarate), an investigational treatment for persistent asthma in patients 12 years of age and older, has been accepted for review by the US Food and Drug Administration (FDA). If approved, Flutiform(TM) will be the first ever fixed-dose medication combining fluticasone, an inhaled corticosteroid (ICS), and formoterol, a long-acting beta agonist (LABA), in the US. Using an environmentally-friendly aerosol propellant, hydrofluoroalkane (HFA), in a metered-dose inhaler, Flutiform(TM) is aimed at the combination ICS/ LABA inhaler market, which is forecast to generate approximately USUSD10 billion worldwide by 2010. As previously announced, the NDA for Flutiform(TM) was submitted to the FDA in Q1 2009. The acceptance of the filing means the FDA has determined that the NDA is sufficiently complete to permit a substantive review. The regulatory review timeline for asthma treatments is typically longer than the standard 10-month Prescription Drug User Fee Act (PDUFA) timeline. Following the acceptance of the NDA for review, an amount of USUSD2 million (GBP1.3 million) is due to SkyePharma from which the filing fee of USUSD1.2 million (GBP0.8 million) will be deducted. Dr. Ken Cunningham, CEO of SkyePharma, said "We are pleased that the FDA has accepted the Flutiform(TM) NDA for review. This is a further step in the development of Flutiform(TM). We believe that, if approved, Flutiform(TM) will provide physicians and asthma patients with an important additional treatment option to help manage this serious, chronic condition." For further information please contact: SkyePharma PLC Ken Cunningham, Chief Executive Officer +44 207 491 1777 Peter Grant, Chief Financial Officer Financial Dynamics Jonathan Birt +44 207 831 3113 Susan Quigley About SkyePharma PLC Using its proprietary drug delivery technologies, SkyePharma develops new formulations of known molecules to provide a clinical advantage and life-cycle extension. The Group has twelve approved products in the areas of oral, inhalation and topical delivery. The Group's products are marketed throughout the world by leading pharmaceutical companies. For more information, visit www.skyepharma.com. About Flutiform(TM) Flutiform(TM) HFA-MDI is a fixed-dose combination of fluticasone and formoterol in a metered dose inhaler (MDI). The product incorporates the most commonly prescribed inhaled anti-inflammatory corticosteroid (fluticasone propionate) and a long-acting beta-agonist (formoterol fumarate) in combination with an environmentally-friendly aerosol propellant hydrofluoroalkane (HFA) and is being developed for asthma. The rights for commercialisation of Flutiform(TM) in the U.S. are licensed to Abbott Respiratory LLC, a wholly-owned subsidiary of Abbott. This information is provided by RNS The company news service from the London Stock Exchange END

Contacts:
RNS
Customer
Services
0044-207797-4400
Email Contact
http://www.rns.com

SOURCE: SkyePharma PLC

http://www2.marketwire.com/mw/emailprcntct?id=144E54181228B62A
http://www.rns.com

For full details for SKYPY click here.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

Tax Relief Bank Levy Wage Garnishment

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.